Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities

(2017) Julia Chang et al.   JAMA Dermatology

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

(2017) Evan J. Lipson et al.   Journal for ImmunoTherapy of Cancer

Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

(2016) J.K. Winkler et al.   BRITISH JOURNAL OF DERMATOLOGY

Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis

(2016) N. Jewel Samadder et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

(2016) Ximena Bonilla et al.   NATURE GENETICS

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

(2016) Sadakatsu Ikeda et al.   npj Genomic Medicine

TP53 mutational status is predictive of pazopanib response in advanced sarcomas

(2015) K. Koehler et al.   ANNALS OF ONCOLOGY

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

(2015) M. Schwaederle et al.   CANCER RESEARCH

Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer

(2015) Diego Marquez-Medina et al.   Future Oncology

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

(2015) Michael R Migden et al.   LANCET ONCOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

(2015) Rabih Said et al.   Oncotarget

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders

(2013) Yasuko Furumoto et al.   BIODRUGS

PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

(2013) B. Weigelt et al.   CLINICAL CANCER RESEARCH

Mutational Landscape of Basal Cell Carcinomas by Whole-Exome Sequencing

(2013) Shyam S. Jayaraman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

Metastatic basal cell carcinoma exhibits reduced actin expression

(2008) Maria C Uzquiano et al.   MODERN PATHOLOGY